# Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma

> **NCT00392990** · PHASE2 · COMPLETED · sponsor: **Northwestern University** · enrollment: 25 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Regimen A
- **DRUG:** Regimen B

## Key facts

- **NCT ID:** NCT00392990
- **Lead sponsor:** Northwestern University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02-06
- **Primary completion:** 2011-12-03
- **Final completion:** 2013-05-28
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2019-10-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00392990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00392990, "Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00392990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*